Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Bullboard Posts
Comment by Leafs4Lifeon Apr 09, 2018 8:14pm
168 Views
Post# 27856423

RE:RE:Revenue projection - a million bucks in 3 weeks or less

RE:RE:Revenue projection - a million bucks in 3 weeks or lessRevenues and profits are different categories.  In my experience, investors in growing industries (like cannabis) tend to care more about revenue growth than earnings per share. The reason I mentioned harbourside taking 50% (which was a guess by the way) was to establish LDS revenue vs total sales of LDS products. I didn't attempt to guess on profits because I don't have the faintest idea what the COGS for reveur happen to be. There will have been some fixed cost relating to R&D on the product that won't show up going forward, would I include that as a one time cost? 

Brad mentioned that he intends to update investors about sales semi regularly (maybe once a month) once products hit shelves. I expect him to announce revenue when he makes these announements. Profits will be disclosed on earnings statements. 

How much profit will LDS make on the sales of Reveur in the next 3 weeks? Brad mentioned something about margins during the AGM so maybe it would be a good idea to check the transcript or rewatch the video. If we knew the revenue and the margin we could kinda guess the profit for LDS.



SCORPION34 wrote: I am long the stock and very patient as most of us here are but just getting product on the shelves should help boost the stock price. Your revenue projections for gross sales may be somewhat accurate but as far as net revenues.... are off. You also need to take into consideration purchasing cannibis, creating the resin, lab tests, packaging, transportation and taxes selling it wholsale. What will be left? Hopefully half of your projection at least. Does anyone know cost per gram?


Bullboard Posts